| Genomic Health Presents Six New Studies Including Four Oral Presentations in Breast, Colon and Renal Cancers at American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire) Genomic Health, Inc. today announced the results of six studies being presented at the American Society of Clinical Oncology Annual Meeting, including an evaluation of biological similarities and differences between stage II and III colon cancer, suggesting a potential role for the Oncotype DX® colon cancer test in patients with stage III disease, pending further study. us.rd.yahoo.com |
Biospherics Acquires Global Patent Rights from University of Kentucky Research Foundation to Develop Tagatose as a Trigylcerides Therapy (PR Newswire) Spherix Incorporated , an innovator in biotechnology for therapy in diabetes, metabolic syndrome, and atherosclerosis; and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that its wholly-owned subsidiary, Biospherics Incorporated, has signed a license agreement with the University of Kentucky Research Foundation . us.rd.yahoo.com |
Enzon Pharma: R&D Spending Will Eventually Pay Off Gaurav Sharma submits:Value investors normally shy away from pharmaceutical companies. These companies tend to gobble up lots of cash to produce drugs whose approval odds are worse than a coin toss. But where there is less crowd, there is more opportunity. A strategy that my favorite investor, Seth Klarman, follows is to buy into companies which already have substantial long term royalty incomes protected by their patents but are burning cash because of management spending it on expensive R&D efforts.One such company is ENZON Pharma (ENZN), which has been completely revitalized by the activist shareholder. Here is a case study of this company as it stands today.Complete Story » seekingalpha.com |
Is This the Top of the Trading Range or Start of a Breakout? Michael Kudrna submits: Monday saw another gap-up followed by dip-buyers showing up to lead us toward a strong close. Volume was decent for this seasonal slow time with this making four straight positive closes in the S&P 500 and eight out of nine positive closes during this rally. Technically speaking, we are overbought but don’t tell that to the bulls right now as the momentum is impressive. The problem I see is nobody fears the downside anymore and that tells me we could be nearing a top. However, if retail numbers meet or beat expectations Tuesday morning, we could see another strong gap-up and even more bullish behavior while ignoring any other economic fears.Complete Story » seekingalpha.com |
Sharps Compliance: PELLA-DRX™ - Video Sharps Compliance Inc. Repurposes Medical Waste into New Products feedproxy.google.com |